Enaltus, a skincare products company and a portfolio company of HealthEdge Investment Partners, has acquired Mitchell-Vance Laboratories, a skincare products manufacturer.
Enaltus provides various branded skincare products including the Kelo-cote and BioCorneum line of scar management products and the Belli Materna line of skincare products for pre and post natal women and infants. The company is based in Suwanee, GA (www.enaltus.com).
Mitchell-Vance Laboratories develops and markets over-the-counter, professional-grade, topical silicone scar treatments sold through more than 20,000 retailers in the U.S. The company is based in Guilford, CT (www.mitchell-vance.com).
HealthEdge Investment Partners makes control or significant minority investments in public and private companies with enterprise values between $10 and $100 million. Sectors of interest include specialty medical products; healthcare services; healthcare information technology; selected pharmaceutical segments; and specialty distribution. The firm was founded in 2005 and is based in Tampa (hwww.healthedgepartners.com).
Investment bank Woodbridge International served as a financial advisor to Mitchell-Vance Laboratories. Woodbridge’s Boston office, led by Brace Carpenter and Tom Hawke, managed the transaction, which was completed within eight months of bringing Mitchell-Vance Laboratories to market. Woodbridge International was founded in 1993 and is headquartered in New Haven, CT. The firm serves clients from its 10 North American offices and locations in the Netherlands, Mexico, Brazil and Honduras (www.woodbridgegrp.com).
© 2013 PEPD • Private Equity’s Leading News Magazine • 4-4-13
